Percutaneous Coronary Intervention Guidance Devices Market Size & Share Analysis - Growth Trends and Forecast (2026 - 2031)

Global Percutaneous Coronary Intervention Guidance Devices Market Trends and Insights

Increasing Burden of Complex Coronary Lesions and Calcified Disease

The percutaneous coronary intervention guidance devices market is benefiting from a larger pool of patients with calcified and anatomically complex lesions that are difficult to assess with angiography alone. Moderate to severe calcification is present in 20% to 30% of patients undergoing invasive coronary angiography, and prevalence rises sharply in older men, which keeps imaging demand structurally tied to aging populations.^{[1]“Calcific Coronary Lesions, Management, Challenges, and a Comprehensive Review,”} The same pattern appears in chronic total occlusion treatment, where the PROGRESS-CTO Registry reported moderate or severe calcification in 49.6% of lesions across 16,916 CTO PCI procedures enrolled between 2012 and 2025.^{[2] “Calcium Modification Strategies in Treatment of Calcified Coronary Chronic Total Occlusions, Insights from the PROGRESS-CTO Registry,”} Clinical evidence has also become harder for hospitals to ignore because the ECLIPSE Trial showed that intravascular imaging guidance lowered 1-year target vessel failure to 9.3% from 13.2% in severely calcified lesions. That outcome keeps the percutaneous coronary intervention guidance devices market tied not only to procedure volume growth, but also to the rising share of procedures that require better lesion preparation, calcium scoring, and post-stent assessment.

Shift Toward Image-Guided and Physiology-Guided PCI

The percutaneous coronary intervention guidance devices market is also being lifted by a wider shift from angiography-only workflows toward imaging-guided and physiology-guided PCI. Integrated systems now let physicians access IVUS, OCT, and pressure-based tools on one console, which reduces setup burden and supports more consistent cath lab workflows. A 2025 meta-analysis covering 22 clinical trials found that intravascular imaging-guided PCI reduced cardiac death by 45%, target lesion failure by 29%, and definite stent thrombosis by 48% against angiography guidance alone.^{[3]“Artificial Intelligence in Intravascular Imaging for Percutaneous Coronary Interventions, A New Era of Precision,”} The OCTIVUS Trial also showed that patients who achieved stent optimization had a 52% relative reduction in target vessel failure, and the benefit was strongest under OCT guidance.^{[4]“Impact of Artificial Intelligence-Enhanced Optical Coherence Tomography Software on Percutaneous Coronary Intervention Decisions,”} These results are changing procurement behavior because hospitals now see guidance platforms as tools that support both better outcomes and closer compliance with updated practice standards.

AI-Assisted Lesion Assessment and Workflow Automation

AI is becoming a practical adoption driver in the percutaneous coronary intervention guidance devices market because it reduces the time and expertise needed to interpret pullbacks and complete procedural planning. The strongest immediate value is workflow efficiency, since lower-volume programs often hesitate to use intravascular imaging when interpretation depends on a small number of highly experienced operators. A 2025 study found that Abbott’s Ultreon AI-OCT system improved stent sizing accuracy by 2.83 times and reduced interpretation time against conventional software. The FLASH Trial also demonstrated non-inferiority of AI-QCA-assisted PCI to OCT-guided PCI in post-procedural minimal stent area across 400 patients in 13 South Korean centers. As a result, the percutaneous coronary intervention guidance devices market is starting to expand from a hardware-led category into a software-enabled platform space where efficiency and consistency matter almost as much as image quality.

Reimbursement Support for Intravascular Imaging in Mature Markets

The percutaneous coronary intervention guidance devices market continues to gain from payment structures that reward imaging use in the most complex procedures. In the United States, the FY2026 inpatient payment framework kept separate payment support for IVUS and FFR in the hospital inpatient setting, while stented PCI MS-DRG payments reached USD 22,929. CMS also finalized new complex PCI code 92930 for 2026, which gives greater recognition to multi-lesion and bifurcation work where intravascular guidance is most often used. Japan remains the clearest example of how reimbursement can change clinical behavior, with more than 80% of PCI procedures performed under intravascular imaging guidance. This keeps the percutaneous coronary intervention guidance devices market more responsive to policy design in mature systems than many other device categories.

High Capital and Recurring Catheter Cost

The percutaneous coronary intervention guidance devices market remains constrained by the full ownership cost of consoles, software, and single-use catheters. Hospitals do not only evaluate the base platform price, but they also judge whether recurring catheter use can be justified across a broad PCI caseload under bundled payment structures. Boston Scientific’s 2026 reimbursement guide notes that IVUS and FFR are not separately billable in ambulatory surgical centers, which leaves institutions to recover costs through coding structures that many ASC administrators still find difficult to use. That issue is even more acute in emerging markets, where capital budgets are tighter, and imaging is reserved for the highest-risk cases rather than normalized across routine procedures. As a result, the percutaneous coronary intervention guidance devices market still depends heavily on premium hospitals and referral centers that can support both hardware acquisition and steady disposable pull-through.

Shortage of Trained Interventional Cardiologists

Workforce limits are another structural restraint on the percutaneous coronary intervention guidance devices market because procedure growth cannot accelerate if trained operators do not keep pace. The 2025 interventional cardiology fellowship match left 71 positions unfilled across 49 programs, which SCAI described as evidence of a shrinking trainee pipeline. This shortage has a direct effect on guidance adoption because advanced imaging and physiology tools are used most consistently by teams with stronger training depth and case volume. The same gap is also pushing hospitals toward AI-enabled systems that can help less experienced operators interpret pullbacks and plan stent sizing more efficiently. Even so, the percutaneous coronary intervention guidance devices market cannot fully offset the impact of staffing shortages when recruitment, retention, and training remain under pressure.

*Our forecasts treat driver/restraint impacts as directional, not additive. The impact forecasts reflect baseline growth, mix effects, and variable interactions.

Segment Analysis

By Product Type: IVUS Dominance Sustains While Wire-Free Physiology Closes the Gap

Intravascular ultrasound systems accounted for 36.74% of the percutaneous coronary intervention guidance devices market share in 2025, which kept IVUS as the leading product type. That lead reflected long physician familiarity, a mature catheter supply chain, and strong use in ostial and left-main disease, where OCT flush requirements can limit practicality. The segment also benefited from the shift toward higher-definition IVUS catheters in complex PCI, where physicians want deeper vessel assessment together with clearer plaque and calcium visualization. OCT remained the second-largest product category, and comparative evidence continued to narrow perceived outcome differences between the two modalities. A 2024 meta-analysis across 6 randomized controlled trials and 4,402 patients found no significant difference between OCT-guided and IVUS-guided PCI in MACE, cardiac mortality, or stent thrombosis.

The percutaneous coronary intervention guidance devices market is seeing its fastest product-type momentum in iFR systems, which are projected to grow at a 10.45% CAGR through 2031. The main appeal is the adenosine-free workflow, since it reduces procedure time, avoids added drug use, and simplifies the protocol for routine physiology assessment. FFR systems still hold a complementary role, but the competitive pressure around wire-free and angio-derived options is becoming clearer. The FLAVOUR II Trial published in 2025 showed that an angiography-derived FFR-guided strategy was non-inferior to IVUS guidance for 12-month clinical outcomes, which supports a gradual shift away from some wire-based cases. Accessories and disposables remain central to the percutaneous coronary intervention guidance devices industry because guidewires, imaging catheters, and flush kits keep recurring revenue tied closely to console placement and physician loyalty.

By Technology: Physiological Guidance and AI Expand the Platform Mix

IVUS-based guidance held a 34.68% technology share in 2025, supported by its installed base and its practical value in lesions that need plaque burden and calcification depth assessment. The modality remains especially important in cases where OCT contrast flushing is less suitable, which gives IVUS a durable role in more complex coronary anatomy. This leadership also reflects the fact that many hospitals have already built their workflow around IVUS consoles before the current wave of AI and multimodality launches. At the same time, the technology mix is widening as hospitals compare image-led guidance with physiology-led strategies for selected lesions. This leaves the percutaneous coronary intervention guidance devices market less dependent on a single guidance method than it was only a few years ago.

FFR and iFR physiological guidance is forecast to grow at a 12.89% CAGR through 2031, which makes it the fastest-growing technology group. The CathWorks ALL-RISE Trial, presented at ACC.26, randomized 1,930 patients across 59 global sites and showed that FFRangio delivered similar clinical outcomes to invasive wire-based physiology assessment. AI-enabled PCI guidance is also becoming more credible as a technology layer rather than a marketing feature. A study in the Journal of the Society for Cardiovascular Angiography & Interventions found that Abbott’s Ultreon AI platform produced more accurate, less variable, and more time-efficient PCI planning decisions than conventional software across operator experience levels. This shift gives the percutaneous coronary intervention guidance devices industry a broader competitive field, where imaging depth, physiology integration, and software productivity all influence capital spending decisions.

By Application: Complex PCI Becomes the Highest-Growth Clinical Use Case

Stent selection and optimization contributed 32.59% of application revenue in 2025, which made it the largest use case in the percutaneous coronary intervention guidance devices market. This position is logical because post-stent sizing, expansion, and apposition checks are the clearest point at which intravascular guidance can show immediate procedural value. The OCTIVUS Trial reinforced that value by showing that stent optimization was linked to a 52% relative reduction in target vessel failure. Hospitals can therefore justify imaging use more easily when the benefit is tied directly to a measurable procedural endpoint. This application remains the base layer of demand because it connects clinical improvement, physician confidence, and payment support in the most visible way.

Complex PCI guidance is projected to expand at a 11.72% CAGR in the percutaneous coronary intervention guidance devices market through 2031, making it the fastest-growing application. Growth is tied to the rising share of multi-vessel disease, bifurcations, left-main interventions, and calcified lesions in contemporary PCI caseloads. The 2025 guideline upgrade for intravascular imaging in complex and left-main PCI within acute coronary syndrome has strengthened this shift by treating advanced guidance as standard practice in high-risk anatomy. Lesion assessment is also gaining relevance as AI software automates plaque characterization and calcium measurement, and deep-learning tools have already shown expert-comparable plaque segmentation in validated OCT datasets. CTO and bifurcation planning remain more specialized, but AI-based planning tools described in 2025 also showed reduced procedural time and radiation exposure, which may gradually widen adoption beyond expert centers.

By End User: Outpatient Migration Reshapes Buying Patterns

Hospitals held 60.43% of end-user revenue in 2025, which kept them as the core buyer group in the percutaneous coronary intervention guidance devices market. Their lead rested on the concentration of cath lab infrastructure, credentialed operators, and reimbursement pathways for complex PCI in tertiary and academic centers. Hospitals also remain the primary setting for left-main, bifurcation, and heavily calcified cases, which are the procedures most likely to use advanced imaging and physiology tools. This gives large health systems continued influence over platform placements, upgrade cycles, and preferred vendor ecosystems. In the near term, hospital demand still anchors most revenue because complex care pathways and capital budgets remain concentrated there.

Ambulatory surgical centers are projected to grow at a 13.67% CAGR through 2031, which makes them the fastest-growing end-user category and the most important new procurement channel. A MedPAC review found that cardiology was the fastest-growing ASC specialty between 2018 and 2023, and CMS added 86 new cardiovascular procedure codes to the ASC Covered Procedures List in 2026. A nationwide study also found that ASC procedural volume is expected to rise by 21% between 2024 and 2034, while the American College of Cardiology launched its Cardiovascular ASC Registry Suite in early 2024. These changes matter for the percutaneous coronary intervention guidance devices market size because vendors will need smaller-footprint systems, simpler workflows, and different pricing models for outpatient economics. Specialty cardiology centers and standalone catheterization laboratories remain smaller in scale, but they add a growing layer of demand in settings that value procedural efficiency and flexible capital deployment.

Geography Analysis

North America held 39.58% of the percutaneous coronary intervention guidance devices market share in 2025, which kept it as the largest regional contributor. The region benefits from mature reimbursement architecture, a dense base of high-volume PCI centers, and the commercial presence of the leading platform vendors. U.S. guideline changes continue to support capital and consumable demand because hospitals increasingly link imaging use with expected standards of care in complex PCI. Payment support also remains stronger here than in most other regions, even if coding details still vary by site of care. Canada and Mexico add to regional volume, though procurement timelines and uneven tertiary access still limit the pace of broader adoption.

Europe remained the second-largest region in 2025, with Germany, France, and the United Kingdom acting as the main centers for advanced intravascular guidance use. The region combines an established interventional cardiology base with growing demand for system refreshes as older platforms approach replacement cycles. Philips strengthened its European position in March 2026 by launching IntraSight Plus with both FDA and CE marks, which supports hospitals seeking a combined IVUS and physiology workflow on one screen. Adoption is still uneven across the region because high-volume centers move faster than community hospitals where capital constraints keep angiography-guided practice more common.

Asia-Pacific is projected to grow at a 14.73% CAGR in the percutaneous coronary intervention guidance devices market size through 2031, making it the fastest-growing region. Japan remains the benchmark market because more than 80% of PCI procedures are already performed under intravascular imaging guidance. That level of use shows how reimbursement alignment and clinical culture can reinforce each other over time. The broader region also benefits from procedural volume growth, expanding cath lab infrastructure, and rising interest in integrated and hybrid platforms. South Korea is important because it has contributed pivotal evidence in AI-assisted PCI workflow validation, including the FLASH Trial. India and Southeast Asia remain longer-conversion markets where private hospital networks are adding capability, but reimbursement support for adjunct imaging is still inconsistent. The Middle East and Africa are growing from a small base, led by tertiary investment in Gulf countries and early adoption in South Africa. South America remains anchored by Brazil, though reimbursement limits and approval friction still constrain wider use across public systems.